BES_Mark.jpg
OCUGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm
April 11, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against...
Schall Firm Logo 2.jpg
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
April 11, 2024 20:58 ET | Schall Law
The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
July 30, 2021 - ROSEN LOGO.jpg
OCGN INVESTOR NEWS: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – OCGN
April 11, 2024 19:18 ET | The Rosen Law Firm PA
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Ocugen,...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
April 08, 2024 06:30 ET | Ocugen
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
BES_Mark.jpg
OCUGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Ocugen, Inc. on Behalf of Ocugen Stockholders and Encourages Investors to Contact the Firm
April 02, 2024 21:00 ET | Bragar Eagel & Squire
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ocugen, Inc. (“Ocugen” or...
Block & Leviton LLP Logo
SHAREHOLDER ALERT: Ocugen Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
April 02, 2024 11:06 ET | Block & Leviton LLP
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Ocugen, Inc. (NASDAQ: OCGN) for potential securities law violations. Investors who have lost money in their Ocugen,...
ocugen_4C_LOGO (002).png
Ocugen to Present at Pharma Market Research Conference
January 31, 2024 08:00 ET | Ocugen
MALVERN, Pa., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
November 09, 2023 06:30 ET | Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
September 21, 2023 07:30 ET | Ocugen
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
August 21, 2023 16:32 ET | Ocugen
Conference Call and Webcast Tomorrow at 8:30 a.m. ET • Investigational New Drug (IND) Applications Cleared for Novel Gene Therapies for Geographic Atrophy Secondary to AMD and for Stargardt Disease ...